poisar

Stocks · News reference

Cullinan Therapeutics Announces Positive Feedback From FDA Following End-Of-Phase 1 Meeting For CLN-049, FLT3xCD3 T Cell Engager Being Evaluated In Patients With Acute Myeloid Leukemia

Jul 28, 2026, 11:10 AMBenzinga Newsdesk

Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan"))), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CGEM
Source
benzinga
Observed
Jul 28, 2026, 11:10 AM
Checked
Jul 28, 2026, 11:10 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 19, 2026, 4:11 PMBenzinga Newsdesk

    Taiho Oncology And Cullinan Therapeutics Say Results From Planned Interim Analysis Of Phase 3 REZILIENT3 Trial Selected For Presentation In Presidential Symposium 2 At IASLC 2026 World Conference On Lung Cancer

    Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLCTaiho

    Read original at benzinga
    CGEM